1-4 of 4
Jean Cui
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1/1b Open-Label, Dose Escalation, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Leukemic Activity of the Orally Available CDC-like Kinase Inhibitor, BH-30236, in Adults with R/R AML or HR-MDS

Eytan M. Stein, Leora Boussi, Alice Mims, Justin M. Watts, Gabriel N Mannis, Hongtao Liu, David Sallman, Farhad Ravandi, Gary J. Schiller, Eunice S. Wang, Brian J. Ball, J. Jean Cui, Jihao Zhou, Armin Graber, Zachary Zimmerman, Stephen Anthony Strickland
Journal: Blood
Blood (2024) 144 (Supplement 1): 5998.
https://doi.org/10.1182/blood-2024-204046
Published: 2024
Journal Articles

BH-30236, a Novel Macrocyclic Clk Inhibitor Modulating Aberrant RNA Splicing, Demonstrates Potent Anti-Cancer Activity Against Myeloid Malignancies

Wei Deng, Ping Jiang, Danan Li, Dayong Zhai, Nancy Ling, Zhenping Wang, Yue Hu, Evan Rogers, Levan Darjania, Jeff Whitten, Jesse Shao, Antonio Montalban, Eugene Rui, J. Jean Cui
Journal: Blood
Blood (2024) 144 (Supplement 1): 5807.
https://doi.org/10.1182/blood-2024-208789
Published: 2024
Journal Articles

Novel Multikinase Clk Inhibitor BH-30236 Targets Hematological Malignancies through Alternative Splicing Regulation

Nancy Ling, Gregory Sims, Ping Jiang, Wei Deng, Dayong Zhai, Danan Li, Zhenping Wang, Yue Hu, Eric Wang, Armin Graber, J. Jean Cui
Journal: Blood
Blood (2024) 144 (Supplement 1): 5806.
https://doi.org/10.1182/blood-2024-208576
Published: 2024
Journal Articles

Accidental and Intentional Overdose of Imatinib: a Report of Outcome and Side Effect of 46 Cases.

François Guilhot, MD, Alan K. Hatfield, MD, FACP, Frederic Millot, Lydia Roy, Mathieu Molimard, Jean Cui
Journal: Blood
Blood (2009) 114 (22): 4273.
https://doi.org/10.1182/blood.V114.22.4273.4273
Published: 2009